CSIMarket
 


Seelos Therapeutics inc   (SEEL)
Other Ticker:  
 

Cumulative Seelos Therapeutics Inc 's Working Capital Ratio for Trailing Twelve Months Period

SEEL's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

SEEL Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth 54.73 % 69.13 % 312.16 % 287.97 % 203.58 %
Y / Y Current Assets Growth -76.17 % -84.72 % -77.5 % -66.63 % -72.83 %
Working Capital Ratio for Trailing Twelve Months Period 0.28 0.41 0.7 1.41 2.67
Total Ranking # 2359 # 3583 # 3518 # 2765 # 1832
Seq. Current Liabilities Growth 10.19 % -37.04 % 43.14 % 55.82 % 20.45 %
Seq. Current Assets Growth -12.69 % -47.76 % -49.77 % 4.01 % -44.03 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Due to increase in Current Liabilities in the IV. Quarter to $39 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 0.28 below Seelos Therapeutics Inc average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 213 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Seelos Therapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about SEEL
Working Capital Ratio SEEL in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 214
Sector # 489
S&P 500 # 2379


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
9.55 2.89 0.28
(Mar 31 2022)   (Dec 31 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Cingulate Inc   0.75 
Aeon Biopharma inc   0.73 
Comera Life Sciences Holdings Inc   0.72 
International Stem Cell Corporation  0.70 
Dmk Pharmaceuticals Corporation  0.67 
Optinose Inc   0.67 
Lucy Scientific Discovery Inc   0.66 
Ensysce Biosciences Inc   0.65 
Tenx Keane Acquisition  0.61 
Lannett Company Inc  0.61 
Intelgenx Technologies Corp   0.60 
Agile Therapeutics Inc  0.60 
China Pharma Holdings Inc   0.56 
Abvc Biopharma Inc   0.55 
Takeda Pharmaceutical Company Limited  0.53 
Accustem Sciences Inc   0.52 
Nascent Biotech Inc  0.49 
The Greater Cannabis Company Inc   0.49 
Aditxt Inc   0.49 
Neptune Wellness Solutions Inc   0.47 
Protokinetix Incorporated  0.46 
Redhill Biopharma Ltd   0.44 
Panbela Therapeutics Inc   0.43 
Seelos Therapeutics inc   0.42 
Innovation Pharmaceuticals Inc   0.38 
Celularity Inc   0.35 
Zyversa Therapeutics Inc   0.33 
Allarity Therapeutics Inc   0.32 
Gelesis Holdings Inc   0.32 
Checkpoint Therapeutics Inc   0.31 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com